Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Myocardial Ischemia
Interventions: CLBS14 (low-dose), CLBS14 (high-dose), placebo injection; Biological
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more

Conditions: Tourette Syndrome
Interventions: levodopa solution 2mg/ml for i.v. use, placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: 0.9% Sodium Chloride, Furosemide 40 mg; Drug
Lead sponsor: Adhish Agarwal; Other
Eligibility: 21 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lumbosacral Radiculopathy, Lumbar Radiculopathy
Interventions: Platelet lysate, Saline control; Other
Lead sponsor: Regenexx, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Broomfield, Colorado

Conditions: Smoking, Smoking Cessation
Interventions: Oxytocin, Mindfulness, Saline Solution, Sham mindfulness; Drug · Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Myocardial Infarction
Interventions: CSL112, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 1,267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more

Conditions: Post Traumatic Stress Disorder
Interventions: Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm; Behavioral · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcohol Use Disorder, Inflammatory Response, Craving, Depressed Mood
Interventions: Placebo, Endotoxin; Drug · Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions: Valproic Acid Solution, Isotonic saline solution; Drug
Lead sponsor: Westat; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Necrotizing Soft Tissue Infection, Sepsis
Interventions: HAT, Placebo; Drug
Lead sponsor: Ascension Health; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Labor Pain
Interventions: Terbutaline, Fentanyl, 0.9% NaCl; Drug
Lead sponsor: Kai Schoenhage; Other
Eligibility: 18 Years to 53 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Clostridium Difficile Associated Disease
Interventions: Clostridium difficile vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota

Conditions: Bunion, Hallux Valgus
Interventions: SKY0402, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Brain Diseases, Spinal Cord Diseases
Interventions: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more

Conditions: COVID-19 Immunization, Influenza Immunization
Interventions: IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4), Placebo (0.9% NaCl); Biological · Other
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more

Conditions: Multiple Sclerosis
Interventions: [18F] FZTA; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ozanezumab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Boston, Massachusetts • Grand Rapids, Michigan • Syracuse, New York + 1 more

Conditions: Heart Diseases, Hypertension, Pulmonary
Interventions: tezosentan, placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Stanford, California • New York, New York • Durham, North Carolina + 5 more

Conditions: TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
Interventions: patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 13
States / cities: La Mesa, California • Orange, California • Denver, Colorado + 9 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: 744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more

Conditions: Knee Osteoarthritis
Interventions: PTP-01, Placebo control / saline vehicle; Biological · Other
Lead sponsor: Doron Therapeutics Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more

Conditions: Anaemia
Interventions: Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Mesa, Arizona • Fresno, California • Los Angeles, California + 19 more

Conditions: Enhanced Recovery After Surgery in a Pediatric Population
Interventions: Caffeine citrate 15mg/kg, 0.9% Sodium Citrate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 3 Years to 12 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

ACT34-CMI -- Adult Autologous CD34+ Cells

Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)

Evaluation of Renal Sodium Excretion After Salt Loading in Heart Failure With Preserved Ejection Fraction

Platelet Lysate vs Saline for Lumbosacral Radiculopathy

Mindfulness Training Plus Oxytocin Effects on Smoking Behavior

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.

An Inflammatory Challenge Using Endotoxin

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

HAT for the Treatment of Sepsis Associated With NASTI

Intravenous Terbutaline to Facilitate Labor Epidural Catheter Placement

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

Study of Postoperative Analgesia in Bunionectomy

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population